{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T18:19:02Z","timestamp":1790619542229,"version":"4.1.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T00:00:00Z","timestamp":1738800000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>With the improvement of living standards, an increasing number of patients are presenting with mixed hyperlipidemia. In addition to cholesterol reduction, it is imperative to lower triglyceride levels. The combination of statin and fibrate for reducing lipid levels has commonly been applied in clinical therapy. However, the combination of drugs also increases the risk of adverse events (AEs). In this study, we analyzed the safety signals of rosuvastatin-fenofibrate combination by assessing the publicly available US Food and Drug Administration Adverse Event Reporting System (FAERS), so as to provide a reference for rational clinical use of rosuvastatin and fenofibrate, and reduce the occurrence of related AEs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Reports to the FAERS from 1 January 2004 to 19 March 2020 were analyzed. The proportional report ratio (PRR), reporting odds ratio (ROR), and Bayesian Confidence Propagation Neural Network (BCPNN) analysis were used to extract data from FAERS for suspected signals referring to the combination of rosuvastatin and fenofibrate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 68 safety signals were detected from the top 250 AEs in 3,587 reports, of which 28 signals were not included in the drug labels. All the detected AEs were associated with 12 System Organ Classes (SOC), such as gastrointestinal, musculoskeletal and connective tissue, general diseases, investigations and nervous system. The most frequent AEs were analyzed, and it was found that women generally have a higher susceptibility to experiencing AEs, including pain, nausea, fatigue, myalgia, diarrhea, dyspnea, headache, weakness, and dizziness.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Clinicians should pay more attention to the AEs of gastrointestinal and muscular system during combination therapy, and it is recommended to strengthen pharmaceutical care during clinical application.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1415701","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:13:02Z","timestamp":1738825982000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety assessment of rosuvastatin-fenofibrate combination in the treatment of hyperlipidemia based on FDA\u2019s adverse event reporting system database"],"prefix":"10.3389","volume":"16","author":[{"given":"Qun","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenya","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jsps.2013.02.003","article-title":"Factors affecting the development of adverse drug reactions (Review article)","volume":"22","author":"Alomar","year":"2014","journal-title":"Saudi Pharm. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"e596","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"B3","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2165\/00002018-200225060-00002","article-title":"A data mining approach for signal detection and analysis","volume":"25","author":"Bate","year":"2002","journal-title":"Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e2026053118","DOI":"10.1073\/pnas.2026053118","article-title":"A Bayesian neural network predicts the dissolution of compact planetary systems","volume":"118","author":"Cranmer","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1093\/ije\/dyv346","article-title":"II. Coronary heart disease in the framingham study","volume":"44","author":"Dawber","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"117","DOI":"10.2165\/11597940-000000000-00000","article-title":"One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response","volume":"12","author":"Ferdinand","year":"2012","journal-title":"Am. J. Cardiovasc Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"832557","DOI":"10.3389\/fmed.2022.832557","article-title":"Age-associated risk of liver-related adverse drug reactions","volume":"9","author":"Han","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.11909\/j.issn.1671-5411.2018.01.011","article-title":"2016 Chinese guidelines for the management of dyslipidemia in adults","volume":"15","year":"2018","journal-title":"J. Geriatr. Cardiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"237","DOI":"10.3760\/cma.j.cn112148-20230119-00038","article-title":"Chinese guidelines for lipid management","volume":"38","year":"2023","journal-title":"Chin. Circ. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.jacc.2021.01.047","article-title":"Ultra-processed foods and incident cardiovascular disease in the framingham offspring study","volume":"77","author":"Juul","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1016\/j.jacc.2017.07.745","article-title":"2017 focused update of the 2016 acc expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American college of cardiology task force on expert consensus decision pathways","volume":"70","author":"Lloyd-Jones","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15420\/ecr.2019.06","article-title":"New perspectives on atherogenic dyslipidaemia and cardiovascular disease","volume":"15","author":"Lorenzatti","year":"2020","journal-title":"Eur. Cardiol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"key":"B16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12885-020-07741-0","article-title":"Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1691\/ph.2019.9426","article-title":"Signal detection of oral drug-induced dementia in chronic kidney disease patients using association rule mining and Bayesian confidence propagation neural network","volume":"74","author":"Noguchi","year":"2019","journal-title":"Pharmazie"},{"key":"B18","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Brief. Bioinform"},{"key":"B19","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.atherosclerosissup.2004.08.027","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"5","author":"Pedersen","year":"2004","journal-title":"Atheroscler. Suppl."},{"key":"B20","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1002\/clc.20830","article-title":"Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies","volume":"33","author":"Pepine","year":"2010","journal-title":"Clin. Cardiol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10557-010-6266-4","article-title":"Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study","volume":"24","author":"Roth","year":"2010","journal-title":"Cardiovasc Drugs Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s13300-019-0611-9","article-title":"A survey of the FDA\u2019s adverse event reporting system database concerning urogenital tract infections and sodium glucose cotransporter-2 inhibitor use","volume":"10","author":"Shen","year":"2019","journal-title":"Diabetes Ther."},{"key":"B23","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJM200202143460721","article-title":"Cerivastatin and reports of fatal rhabdomyolysis","volume":"346","author":"Staffa","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1016\/j.jacc.2013.11.002","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"VAN Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B26","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2165\/00002018-200326050-00001","article-title":"Application of quantitative signal detection in the Dutch spontaneous reporting system for adverse drug reactions","volume":"26","author":"Van Puijenbroek","year":"2003","journal-title":"Drug Saf."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1161\/CIR.0000000000000757","article-title":"Heart disease and stroke statistics-2020 update: a report from the American heart association","volume":"141","author":"Virani","year":"2020","journal-title":"Circulation"},{"key":"B28","first-page":"632","article-title":"Bayer pulls cerivastatin (Baycol) from market","volume":"165","author":"Wooltorton","year":"2001","journal-title":"Cmaj"},{"key":"B29","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1159\/000522569","article-title":"Elderly patients with moderate-to-severe ulcerative colitis are more likely to have treatment failure and adverse outcome","volume":"69","author":"Zhang","year":"2023","journal-title":"Gerontology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1415701\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T07:13:08Z","timestamp":1738825988000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1415701\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,6]]},"references-count":29,"alternative-id":["10.3389\/fphar.2025.1415701"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1415701","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,6]]},"article-number":"1415701"}}